Premium
Purinergic Mechanisms in Breast Cancer Development: A Role for Nucleoside Diphosphate Kinase
Author(s) -
Wong Senny,
Yokdang Nucharee,
Speirs Katie,
Buxton Iain L.O.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1104.9
Subject(s) - angiogenesis , purinergic receptor , metastasis , breast cancer , cancer research , mammary tumor , cancer , medicine , tumor microenvironment , biology , endocrinology , receptor
A secreted factor from breast cancer cells, nucleoside diphosphate kinase (NDPK) was shown to promote cell migration, proliferation, and tumor‐mediated angiogenesis, which may support metastasis. The objective of this study was to observe breast cancer development in mice in the presence of inhibitors of purinergic signaling. A luciferase‐tagged murine breast adenocarcinoma 4T1 cell line was injected into the mammary fat of immune competent BALB/C mice that were divided into treatment groups receiving a combination of ellagic acid (EA; NDPK inhibitor) and/or MRS2179 (P2Y1 receptor antagonist) or endostatin (angiogenesis inhibitor as positive control). Tumor growth was measured by imaging tumor luminescence using a Lumina II (Caliper Life Sci.). Serum samples were collected for detection of NDPK levels by enzyme‐linked immunosorbent assay. We found a significant decrease in the primary tumor growth rate at days 21 and 28 with all treatments versus the control. Future work will focus on NDPK present in the serum of women with breast cancer to support or reject the hypothesis that secreted NDPK has a role during early primary tumor and metastasis development and could serve as a biomarker of disease. (Supported by NIH HD053028)